VFA
MCRB icon

Virtus Fund Advisers’s Seres Therapeutics MCRB Stock Holding History

Virtus Fund Advisers’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$358K Buy
+1,765
New +$363K ﹤0.01% 391

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Virtus Fund Advisers's MCRB Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Seres Therapeutics (MCRB) in Q4 2017: 1,765 shares worth $358K. The stake represents ﹤0.01% of the portfolio and ranks #391 among its holdings.

85 funds tracked by Wall St. Rank hold MCRB as of Q4 2017.

  • Virtus Fund Advisers held 1,765 shares of Seres Therapeutics worth $358K as of Q4 2017.
  • Seres Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • Seres Therapeutics made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #391 holding.
  • 85 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.